Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Pharmacother. 2007 Dec;8(17):3009-20.

The importance of treating multiple cardiometabolic risk factors in patients with Type 2 diabetes.

Author information

1
Royal Free Hospital and Royal Free University College Medical School, Department of Clinical Biochemistry, Pond Street, NW3 2QG, London, UK. MIKHAILIDIS@aol.com

Abstract

Type 2 diabetes is usually associated with a number of metabolic and cardiovascular (or cardiometabolic) risk factors that contribute to a high rate of vascular events in these patients. Adipose tissue is now known to secrete a number of pro-inflammatory adipokines that are thought to mediate the link between obesity, insulin resistance and atherosclerosis. Therefore, not only is abdominal obesity a major cardiometabolic risk factor per se, it has the potential to give rise to other emerging risk factors. Plasma concentrations of inflammatory markers, such as C-reactive protein, may provide additional information to guide management and may even represent therapeutic targets. Reducing the risk of cardiovascular events in patients with Type 2 diabetes will involve targeting traditional risk factors and probably novel cardiometabolic factors.

PMID:
18001259
DOI:
10.1517/14656566.8.17.3009
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center